Foghorn Therapeutics (FHTX) versus Its Peers Head to Head Survey

Foghorn Therapeutics (NASDAQ:FHTX) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Foghorn Therapeutics to related companies based on the strength of its risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Volatility and Risk

Foghorn Therapeutics has a beta of 3.22, suggesting that its share price is 222% more volatile than the S&P 500. Comparatively, Foghorn Therapeutics’ peers have a beta of 1.11, suggesting that their average share price is 11% more volatile than the S&P 500.

Institutional and Insider Ownership

61.5% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 9.0% of Foghorn Therapeutics shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Foghorn Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1	6	4	0	2.27
Foghorn Therapeutics Competitors	9828	15119	45430	1586	2.54

Foghorn Therapeutics presently has a consensus target price of $6.14, indicating a potential upside of 228.50%. As a group, “Biotechnology” companies have a potential upside of 102.61%. Given Foghorn Therapeutics’ higher probable upside, equities research analysts plainly believe Foghorn Therapeutics is more favorable than its peers.

Profitability

This table compares Foghorn Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-175.78%	N/A	-31.17%
Foghorn Therapeutics Competitors	-9,046.59%	-199.78%	-30.61%

Valuation and Earnings

This table compares Foghorn Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Foghorn Therapeutics	$30.91 million	-$74.28 million	-1.91
Foghorn Therapeutics Competitors	$691.14 million	$10.43 million	-15.00

Foghorn Therapeutics’ peers have higher revenue and earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Foghorn Therapeutics peers beat Foghorn Therapeutics on 7 of the 13 factors compared.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.